Home » Topics » BioWorld Science

BioWorld Science
RSS

Teijin Pharma presents CDK4/cyclin D3 and/or CDK6/cyclin D3 inhibitors

June 21, 2018

Insights into the orthosteric and allosteric action of C5aR antagonists to guide drug development

June 21, 2018

TG Therapeutics and Novimmune enter global agreement to develop and commercialize TG-1801

June 21, 2018

Xalud initiates phase I trial of XT-150 for osteoarthritic pain

June 21, 2018

Kiyatec initiates 3D-PREDICT study with EV3D assay

June 21, 2018

PATH and SD Biosensor partner on new diagnostic for G6PD deficiency in malaria

June 21, 2018

FDA approves use of Cinryze to prevent angioedema attacks in pediatric patients with HAE

June 21, 2018

Immune Design opens phase III study of CMB-305 for synovial sarcoma

June 21, 2018

Atossa completes dosing in phase I study of topical endoxifen

June 21, 2018

New phase II trial studies arimoclomol for Gaucher's disease

June 21, 2018

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...